Back to top
more

Immunomedics, Inc. (IMMU)

(Delayed Data from NSDQ)

$15.44 USD

15.44
1,829,550

-0.42 (-2.65%)

Updated Oct 18, 2019 03:56 PM ET

Add to portfolio

2-Buy   2      

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.50%
17.69%
9.28%
4.86%
1.63%
10.50%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

D Value | F Growth | F Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Immunomedics (IMMU) Reports Interim Urothelial Cancer Data

Immunomedics (IMMU) presents interim data on sacituzumab govitecan in patients with metastatic urothelial cancer. The company also inks two deals.

RHHBY MRK IMMU SGEN

Zacks Equity Research

Immunomedics (IMMU) Looks Good: Stock Adds 6.1% in Session

Immunomedics (IMMU) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

IMMU ACOR

Zacks Equity Research

Why Is Immunomedics (IMMU) Down 13.1% Since Last Earnings Report?

Immunomedics (IMMU) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

IMMU

Zacks Equity Research

Immunomedics (IMMU) Posts Wider-Than-Expected Loss in Q2

Immunomedics (IMMU) posts wider-than-expected loss and generates no revenues in the second quarter of 2019.

EPZM ACOR IMMU AXGT

Zacks Equity Research

Seattle Genetics (SGEN) Q1 Loss Narrows, Revenues Top Mark

Seattle Genetics (SGEN) betters loss estimates in Q1 and also rides high on revenue beat.

PDLI IMMU SGEN TAK

Zacks Equity Research

Seattle Genetics (SGEN) Q4 Loss Widens, Revenues Top Mark

Seattle Genetics (SGEN) incurs wider-than-expected loss in Q4 but rides high on revenue beat.

MRK SGEN IMMU CELG

Zacks Equity Research

Earnings Preview: Immunomedics (IMMU) Q2 Earnings Expected to Decline

Immunomedics (IMMU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IMMU

Zacks Equity Research

Biotech Stock Roundup: Amgen, Vertex Get EC Nod for Label Expansion of Drugs

A low key week for the biotech sector with regular drug approvals and pipeline updates.

INCY VRTX AMGN ALNY IMMU

Zacks Equity Research

Do Options Traders Know Something About Immunomedics (IMMU) Stock We Don't?

Investors need to pay close attention to Immunomedics (IMMU) stock based on the movements in the options market lately.

IMMU

Zacks Equity Research

Immunomedics Gets CRL From FDA for Breast Cancer Candidate

Immunomedics (IMMU) receives a CRL from the FDA pertaining to the BLA for its lead breast cancer candidate, sacituzumab govitecan.

AZN RHHBY CLVS IMMU

Zacks Equity Research

Immunomedics Enters Into Supply Deal for Breast Cancer Drug

Immunomedics (IMMU) entered into a long-term master supply agreement for lead candidate, sacituzumab govitecan.

AZN BMY CLVS IMMU

Zacks Equity Research

Immunomedics (IMMU) in Focus: Stock Moves 6.1% Higher

Immunomedics (IMMU) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

IMMU GILD

Zacks Equity Research

Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock?

Investors need to pay close attention to Immunomedics (IMMU) stock based on the movements in the options market lately.

IMMU

Zacks Equity Research

Why Immunomedics (IMMU) Could Be Positioned for a Slump

Immunomedics (IMMU) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

ALXN IMMU

Zacks Equity Research

Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock?

Investors need to pay close attention to Immunomedics (IMMU) stock based on the movements in the options market lately.

IMMU

Zacks Equity Research

Immunomedics (IMMU) Reports Q1 Loss, Misses Revenue Estimates

Immunomedics (IMMU) delivered earnings and revenue surprises of -25.00% and -100.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

IMMU

Zacks Equity Research

Seattle Genetics (SGEN) Q3 Loss In Line, Sales Top Mark

Seattle Genetics' (SGEN) loss matches estimates but rides high on revenue beat in Q3.

MRK GNMSF SGEN IMMU

Zacks Equity Research

Immunomedics (IMMU) Looks Good: Stock Adds 5.5% in Session

Immunomedics (IMMU) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

AXON IMMU

Zacks Equity Research

Implied Volatility Surging for Immunomedics (IMMU) Stock Options

Investors need to pay close attention to Immunomedics (IMMU) stock based on the movements in the options market lately.

IMMU

Zacks Equity Research

Is the Options Market Predicting a Spike in Immunomedics (IMMU) Stock?

Investors need to pay close attention to Immunomedics (IMMU) stock based on the movements in the options market lately.

IMMU

Zacks Equity Research

Immunomedics (IMMU) Soars: Stock Adds 10.3% in Session

Immunomedics (IMMU) shares rose more than 10% in the last trading session, amid huge volumes.

GHDX IMMU

Zacks Equity Research

Immunomedics (IMMU) in Focus: Stock Moves 7.9% Higher

Immunomedics (IMMU) was a big mover last session, as the company saw its shares rise nearly 8% on the day.

IMMU

Zacks Equity Research

Options Traders Expect Huge Moves in Immunomedics (IMMU) Stock

Investors in Immunomedics (IMMU) need to pay close attention to the stock based on moves in the options market lately.

IMMU

Zacks Equity Research

Immunomedics (IMMU) Jumps: Stock Rises 5.4%

Immunomedics (IMMU) was a big mover last session, as the company saw its shares more than 5% on the day amid huge volumes.

MYGN IMMU

Zacks Equity Research

Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock?

Investors in Immunomedics (IMMU) need to pay close attention to the stock based on moves in the options market lately.

IMMU